RPG Life Sciences’ wholly owned subsidiary -- RPG Active Pharma (RPGAP) has entered into a Business Transfer Agreement to acquire the Active Pharmaceutical Ingredients (API) and Intermediates business undertaking of Raghava Life Sciences on a going-concern basis through a slump sale. The transaction is subject to customary closing conditions and regulatory approvals.
The acquisition is the next step in RPGAP's consolidation play based on a well-planned buy-and-build strategy to bolster organic growth and create an integrated, scaled API focused organization. Following the recent acquisition of Actis Generics, this transaction broadens RPGAP's manufacturing base, product portfolio, regulatory capabilities and customer access across geographies. The consolidated organization is intended to strengthen RPGAP's participation in the growing API market through greater scale, synergies, deeper integration and focused commercial execution.
RPGAP expects to unlock value through defined synergies across this acquisition, Actis and the wider RPGAP network, including backward integration, improved capacity utilization, cost synergies and selected product transfers.
RPG Life Sciences is an integrated, research-based pharmaceutical company operating in domestic and international markets across branded formulations, global generics and synthetic APIs. The company develops, manufactures and markets a wide range of quality and affordable medicines and remains focused on innovation, operational excellence and sustainable long-term growth.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1917.90 |
| Dr. Reddys Labs. | 1158.25 |
| Cipla | 1397.75 |
| Lupin | 2145.85 |
| Zydus Lifesciences | 1135.35 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: